Biosimilars and biologics litigation in the United States
IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide.
Source: iam-media.com
Mayo Collaborative Servs News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mayo Collaborative Servs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mayo Collaborative Servs Today - Breaking & Trending Today
It's Time To Review Patent Eligibility For Diagnostic Methods
Life science companies invest substantial resources in research and innovation to drive medical advancement. To maintain the momentum of innovation, it is crucial to ensure clarity and certainty in...
Source: marketscreener.com
Can Judge Michel (and John Duffy) Convince the Supreme Court to Revisit Subject Matter Eligibility? | McDonnell Boehnen Hulbert & Berghoff LLP
Einstein's aphorism that doing the same thing over and over again and expecting a different outcome is a hallmark of madness (or at least an inability to learn from the past) inevitably...
Source: jdsupra.com
Stanford Asks Supreme Court to Revisit Subject Matter Eligibility on Diagnostic Claims | McDonnell Boehnen Hulbert & Berghoff LLP
"Hope springs eternal [in the human breast]" (Alexander Pope) and "Insanity is doing the same thing over and over and expecting different results" (the latter attributed variably to...
Source: jdsupra.com
Patent Eligibility of Medical Diagnostic Methods
In CareDx, Inc. v. Natera, Inc., Court of Appeals for the Federal Circuit held CareDx’s patent claims to methods of detecting organ transplant rejection were invalid as patent ineligible under 35 U.S.C. section 101. Claims to medical diagnostics face unique challenges.
Source: natlawreview.com